157 related articles for article (PubMed ID: 8892675)
21. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; GodÃnez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5.
Ahmed M; Dusanter-Fourt I; Dugray A; Dubrez L; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Solary E; Vainchenker W; Turhan AG
Leuk Lymphoma; 2001 Jul; 42(3):445-55. PubMed ID: 11699409
[TBL] [Abstract][Full Text] [Related]
23. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
24. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells.
Le Y; Xu L; Lu J; Fang J; Nardi V; Chai L; Silberstein LE
Am J Hematol; 2009 May; 84(5):273-8. PubMed ID: 19358301
[TBL] [Abstract][Full Text] [Related]
25. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
Wilson-Rawls J; Xie S; Liu J; Laneuville P; Arlinghaus RB
Cancer Res; 1996 Aug; 56(15):3426-30. PubMed ID: 8758906
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
28. Potential role of bcr-abl in the activation of JAK1 kinase.
Henderson YC; Guo XY; Greenberger J; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):145-9. PubMed ID: 9815665
[TBL] [Abstract][Full Text] [Related]
29. STAT signaling in the pathogenesis and treatment of leukemias.
Lin TS; Mahajan S; Frank DA
Oncogene; 2000 May; 19(21):2496-504. PubMed ID: 10851048
[TBL] [Abstract][Full Text] [Related]
30. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
Heath C; Cross NC
J Biol Chem; 2004 Feb; 279(8):6666-73. PubMed ID: 14660670
[TBL] [Abstract][Full Text] [Related]
31. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.
Stewart MJ; Litz-Jackson S; Burgess GS; Williamson EA; Leibowitz DS; Boswell HS
Leukemia; 1995 Sep; 9(9):1499-507. PubMed ID: 7658719
[TBL] [Abstract][Full Text] [Related]
32. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
33. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice.
Levy DE; Gilliland DG
Oncogene; 2000 May; 19(21):2505-10. PubMed ID: 10851049
[TBL] [Abstract][Full Text] [Related]
34. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
35. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
Nosaka T; Kitamura T
Exp Hematol; 2002 Jul; 30(7):697-702. PubMed ID: 12135666
[TBL] [Abstract][Full Text] [Related]
36. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
de Groot RP; Raaijmakers JA; Lammers JW; Jove R; Koenderman L
Blood; 1999 Aug; 94(3):1108-12. PubMed ID: 10419904
[TBL] [Abstract][Full Text] [Related]
37. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.
Sillaber C; Gesbert F; Frank DA; Sattler M; Griffin JD
Blood; 2000 Mar; 95(6):2118-25. PubMed ID: 10706883
[TBL] [Abstract][Full Text] [Related]
38. CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells.
Rhodes J; York RD; Tara D; Tajinda K; Druker BJ
Exp Hematol; 2000 Mar; 28(3):305-10. PubMed ID: 10720695
[TBL] [Abstract][Full Text] [Related]
39. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
Qiu X; Guo G; Chen K; Kashiwada M; Druker BJ; Rothman PB; Chen JL
Neoplasia; 2012 Jun; 14(6):547-58. PubMed ID: 22787435
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
Donato NJ; Wu JY; Zhang L; Kantarjian H; Talpaz M
Blood; 2001 May; 97(9):2846-53. PubMed ID: 11313280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
